Jay Olson
Stock Analyst at Oppenheimer
(4.30)
# 349
Out of 5,182 analysts
250
Total ratings
45.54%
Success rate
19.77%
Average return
Main Sectors:
Stocks Rated by Jay Olson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Maintains: Outperform | $250 → $275 | $173.59 | +58.42% | 27 | Apr 1, 2026 | |
| PASG Passage Bio | Initiates: Outperform | $30 | $10.37 | +189.44% | 1 | Mar 31, 2026 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $44 → $36 | $5.02 | +617.13% | 5 | Mar 18, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $540 → $600 | $436.90 | +37.33% | 2 | Mar 10, 2026 | |
| BIOA BioAge Labs | Initiates: Outperform | $60 | $16.02 | +274.53% | 1 | Feb 25, 2026 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Perform | $21 → $23 | $21.05 | +9.26% | 16 | Feb 6, 2026 | |
| RVMD Revolution Medicines | Maintains: Outperform | $75 → $150 | $134.93 | +11.17% | 10 | Jan 27, 2026 | |
| CHRS Coherus Oncology | Initiates: Outperform | $10 | $1.70 | +488.24% | 1 | Jan 22, 2026 | |
| PRAX Praxis Precision Medicines | Maintains: Outperform | $250 → $750 | $318.34 | +135.60% | 3 | Dec 15, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Outperform | $28 → $58 | $52.68 | +10.10% | 4 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $650 | $525.81 | +23.62% | 12 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $2.18 | +129.36% | 1 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $90 | $75.47 | +19.25% | 4 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $30 | $5.61 | +434.76% | 3 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $14 | $3.72 | +276.34% | 1 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $10.32 | - | 15 | May 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $65 | $2.92 | +2,126.03% | 1 | May 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $65 | $0.90 | +7,123.02% | 5 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $13 | $1.10 | +1,081.82% | 3 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $90 | $79.58 | +13.09% | 6 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $42 | $19.20 | +118.75% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $41 → $33 | $43.97 | -24.95% | 6 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $40 | $13.92 | +187.36% | 9 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $20 | $5.24 | +281.68% | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $5.44 | +451.47% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $82 | $94.07 | -12.83% | 14 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $138 | $35.11 | +293.11% | 8 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $1.86 | +330.11% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $380 | $346.19 | +9.77% | 23 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $216 → $219 | $126.62 | +72.96% | 15 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $12 | $3.14 | +282.78% | 6 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 | $3.84 | +368.75% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 | $27.25 | +266.97% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $95 | $53.95 | +76.09% | 6 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $0.71 | +3,400.42% | 1 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 | $0.97 | +827.84% | 4 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,200 → $500 | $1.38 | +36,131.88% | 4 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $25 → $21 | $14.22 | +47.73% | 9 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $7.27 | - | 2 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $84 | $17.60 | +377.41% | 1 | Mar 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $2.03 | - | 3 | Jul 11, 2017 |
Biogen
Apr 1, 2026
Maintains: Outperform
Price Target: $250 → $275
Current: $173.59
Upside: +58.42%
Passage Bio
Mar 31, 2026
Initiates: Outperform
Price Target: $30
Current: $10.37
Upside: +189.44%
Bicycle Therapeutics
Mar 18, 2026
Maintains: Outperform
Price Target: $44 → $36
Current: $5.02
Upside: +617.13%
Vertex Pharmaceuticals
Mar 10, 2026
Maintains: Outperform
Price Target: $540 → $600
Current: $436.90
Upside: +37.33%
BioAge Labs
Feb 25, 2026
Initiates: Outperform
Price Target: $60
Current: $16.02
Upside: +274.53%
ACADIA Pharmaceuticals
Feb 6, 2026
Maintains: Perform
Price Target: $21 → $23
Current: $21.05
Upside: +9.26%
Revolution Medicines
Jan 27, 2026
Maintains: Outperform
Price Target: $75 → $150
Current: $134.93
Upside: +11.17%
Coherus Oncology
Jan 22, 2026
Initiates: Outperform
Price Target: $10
Current: $1.70
Upside: +488.24%
Praxis Precision Medicines
Dec 15, 2025
Maintains: Outperform
Price Target: $250 → $750
Current: $318.34
Upside: +135.60%
Terns Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $28 → $58
Current: $52.68
Upside: +10.10%
Nov 20, 2025
Maintains: Outperform
Price Target: $600 → $650
Current: $525.81
Upside: +23.62%
Oct 21, 2025
Initiates: Outperform
Price Target: $5
Current: $2.18
Upside: +129.36%
Oct 8, 2025
Maintains: Outperform
Price Target: $84 → $90
Current: $75.47
Upside: +19.25%
Sep 25, 2025
Maintains: Outperform
Price Target: $21 → $30
Current: $5.61
Upside: +434.76%
Jul 29, 2025
Initiates: Outperform
Price Target: $14
Current: $3.72
Upside: +276.34%
May 27, 2025
Downgrades: Perform
Price Target: n/a
Current: $10.32
Upside: -
May 21, 2025
Initiates: Outperform
Price Target: $65
Current: $2.92
Upside: +2,126.03%
May 15, 2025
Maintains: Outperform
Price Target: $80 → $65
Current: $0.90
Upside: +7,123.02%
May 14, 2025
Maintains: Outperform
Price Target: $15 → $13
Current: $1.10
Upside: +1,081.82%
Mar 14, 2025
Upgrades: Outperform
Price Target: $90
Current: $79.58
Upside: +13.09%
Mar 3, 2025
Maintains: Outperform
Price Target: $50 → $42
Current: $19.20
Upside: +118.75%
Jan 24, 2025
Downgrades: Perform
Price Target: $41 → $33
Current: $43.97
Upside: -24.95%
Jan 13, 2025
Maintains: Outperform
Price Target: $60 → $40
Current: $13.92
Upside: +187.36%
Dec 11, 2024
Maintains: Outperform
Price Target: $80 → $20
Current: $5.24
Upside: +281.68%
Dec 6, 2024
Initiates: Outperform
Price Target: $30
Current: $5.44
Upside: +451.47%
Oct 30, 2024
Maintains: Outperform
Price Target: $81 → $82
Current: $94.07
Upside: -12.83%
Sep 25, 2024
Reiterates: Outperform
Price Target: $138
Current: $35.11
Upside: +293.11%
Aug 14, 2024
Assumes: Outperform
Price Target: $8
Current: $1.86
Upside: +330.11%
Aug 7, 2024
Maintains: Outperform
Price Target: $380
Current: $346.19
Upside: +9.77%
Aug 2, 2024
Maintains: Outperform
Price Target: $216 → $219
Current: $126.62
Upside: +72.96%
Jun 18, 2024
Maintains: Perform
Price Target: $12
Current: $3.14
Upside: +282.78%
May 15, 2024
Maintains: Outperform
Price Target: $18
Current: $3.84
Upside: +368.75%
May 15, 2024
Maintains: Outperform
Price Target: $100
Current: $27.25
Upside: +266.97%
May 10, 2024
Maintains: Outperform
Price Target: $102 → $95
Current: $53.95
Upside: +76.09%
Apr 12, 2024
Initiates: Outperform
Price Target: $25
Current: $0.71
Upside: +3,400.42%
Mar 27, 2024
Maintains: Outperform
Price Target: $9
Current: $0.97
Upside: +827.84%
Nov 30, 2023
Maintains: Outperform
Price Target: $1,200 → $500
Current: $1.38
Upside: +36,131.88%
Nov 22, 2023
Maintains: Perform
Price Target: $25 → $21
Current: $14.22
Upside: +47.73%
Oct 13, 2022
Downgrades: Perform
Price Target: n/a
Current: $7.27
Upside: -
Mar 20, 2018
Maintains: Outperform
Price Target: $70 → $84
Current: $17.60
Upside: +377.41%
Jul 11, 2017
Upgrades: Outperform
Price Target: n/a
Current: $2.03
Upside: -